用于检测、定量和定位抗原与抗体的技术——ELISA、免疫印迹、免疫组化与流式细胞术。以下是我们知识库中标注该主题的实验方案、常见问题与技术文章。
Antibody–drug conjugates (ADCs) use tumor cell-surface antigens to achieve antibody recognition and payload delivery. HER2, TROP2, Nectin-4, FRα, and c-Met have received substantial clinical validation, while HER3, B7-H3, CLDN18.2, and DLL3 continue to enter ADC development pipelines. The ...
抗体偶联药物（antibody–drug ...
受体酪氨酸激酶（receptor tyrosine kinase，RTK）通过酪氨酸磷酸化调控细胞增殖、存活、迁移和分化。RTK突变、扩增、融合或异常表达可持续激活MAPK、PI3K/AKT、STAT和PLC等信号通路，推动肿瘤发生并影响分子分型、靶向治疗及耐药。
Receptor tyrosine kinases (RTKs) regulate cell proliferation, survival, migration, and differentiation through tyrosine phosphorylation. RTK mutations, amplifications, fusions, or abnormal expression can continuously activate MAPK, PI3K/AKT, STAT, PLC, and other signaling pathways, thereby ...
非小细胞肺癌具有显著的组织学和分子异质性。EGFR、ALK、ROS1、KRAS、BRAF、RET、MET和HER2等异常可持续激活肿瘤细胞增殖与存活信号，并形成具有不同生物学特征和药物敏感性的分子亚型。
Non-small cell lung cancer exhibits substantial histological and molecular heterogeneity. Alterations involving EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, HER2, and other oncogenic drivers can continuously activate tumor-cell proliferation and survival signaling and generate molecular subtypes with ...
HER3 strengthens PI3K/AKT survival signaling by forming heterodimers with receptors such as HER2 and EGFR and contributes to bypass compensation, maintenance of drug resistance, and tumor progression under multiple therapeutic pressures.
HER3通过与HER2、EGFR等受体形成异源二聚体，强化PI3K/AKT生存信号，并在多种治疗压力下参与旁路补偿、耐药维持和肿瘤进展。
The ErbB family pathway is a major module within receptor tyrosine kinase networks. Its key feature is not activation of a single receptor in isolation, but rather the coordinated determination of biological outcomes such as cell proliferation, survival, differentiation, and migration through ...
ErbB家族通路是受体酪氨酸激酶网络中的重要模块，其关键不在于单一受体被激活，而在于配体识别、受体二聚化、胞内酪氨酸位点磷酸化以及多条下游信号轴共同决定细胞增殖、存活、分化和迁移等生物学结果。
常与免疫学实验一起研究的技术。
危险品化学品经营许可证（带存储）